SLC25A1 (E7B2B) Rabbit mAb #97835
- WB
- IP
- IHC
- IF
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 28 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IHC-Immunohistochemistry
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Simple Western™ | 1:50 - 1:250 |
| Immunoprecipitation | 1:200 |
| Immunohistochemistry (Paraffin) | 1:300 - 1:1200 |
| Immunofluorescence (Frozen) | 1:50 |
| Immunofluorescence (Immunocytochemistry) | 1:50 - 1:200 |
Storage
Protocol
Specificity / Sensitivity
SLC25A1 (E7B2B) Rabbit mAb recognizes endogenous levels of total SLC25A1 protein. Species cross-reactivity for IHC-P is human only.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the mitochondrial matrix-facing domains of human SLC25A1 protein. The antigen has been further characterized as corresponding to residues surrounding Arg173 of human SLC25A1 protein.
Background
Members of the solute carrier 25 (SLC25) family transport molecules over the mitochondrial inner membrane (1,2). Mutations in these carriers often result in rare but severe pathologies (3). SLC25A1 (tricarboxylate transport protein, CIC, or citrate transport protein) transports citrate from the inner mitochondrial matrix to the cytosol in exchange for malate. This function makes it a key source of cytoplasmic acetyl-CoA and downstream lipid biosynthesis (4). Mutations in SLC25A1 result in D-2- and L-2-hydroxyglutaric aciduria, causing lowered levels of citrate and isocitrate in urine, with elevated urinary levels of other TCA-cycle intermediates (3). Cancer cells have elevated mitochondrial membrane potential and require SLC25A1 to maintain and promote tumorigenesis (5,6). SLC25A1 is a transcriptional target of p53, and inhibiting SLC25A1 activity can blunt mutant p53-driven tumor growth (6). Inhibitors of SLC25A1 have been found to slow the growth of pancreatic and non-small cell lung cancers (7,8).
- Ruprecht, J.J. and Kunji, E.R.S. (2021) Annu Rev Biochem 90, 535-558.
- Kunji, E.R.S. et al. (2020) Physiology (Bethesda) 35, 302-327.
- Palmieri, F. et al. (2020) Biomolecules 10, 655. doi: 10.3390/biom10040655.
- Coleman, P.S. and Parlo, R.A. (2021) Front Cell Dev Biol 9, 626316.
- Rochette, L. et al. (2020) Molecules 25, 2417. doi: 10.3390/molecules25102417.
- Kolukula, V.K. et al. (2014) Oncotarget 5, 1212-25.
- Liu, J. et al. (2020) J Proteome Res 19, 3825-3836.
- Fernandez, H.R. et al. (2018) Cell Death Differ 25, 1239-1258.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.